Moderna’s Mixed Performance: Strong Spikevax Sales Drive Q3 Success Amid mRESVIA Uncertainties, Resulting in Hold Rating
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
FiercePharma7d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
BioSpace7d
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Moderna posts surprise profit as COVID vaccine sales exceed expectations
Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...
Moderna swings to profits as new COVID shot powers Q3 beat
Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...
Zacks.com on MSN6d
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion ...
Moderna EPS Beats Estimates, Sales Rise
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
The Motley Fool on MSN7d
These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over
The bottom five are (in order from steepest price decline to narrowest): Walgreens Boots Alliance (NASDAQ: WBA), Estée Lauder ...
IPWatchdog28d
Northwestern University Sues Moderna Over Spikevax Vaccine
According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...